Journal of the Korean Academy of Child and Adolescent Psychiatry

대한소아청소년정신의학회 (Korean Academy of Child and Adolescent Psychiatry)
권호 표지
DOI QR코드

DOI QR Code

주의력결핍 과잉행동장애 한국형 치료 권고안 개정안(III) - 약물치료 -

The Revised Korean Practice Parameter for the Treatment of Attention-Deficit Hyperactivity Disorder (III) - Pharmacological Treatment -

  • 김효원 (울산대학교 의과대학 서울아산병원 정신건강의학교실) ;
  • 김은주 (연세대학교 의과대학 강남세브란스병원 정신건강의학교실) ;
  • 김지훈 (부산대학교 의학전문대학원 정신건강의학교실) ;
  • 박장호 (울산대학교 의과대학 울산대학교병원 정신건강의학교실) ;
  • 반건호 (경희대학교 의학전문대학원 정신건강의학교실) ;
  • 이연정 (순천향대학교 서울병원 정신건강의학과) ;
  • 정경운 (가톨릭관동대학교 국제성모병원 정신건강의학교실) ;
  • 신동원 (성균관대학교 의과대학 강북삼성병원 정신건강의학교실)
  • Kim, Hyo-Won (Department of Psychiatry, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Kim, Eunjoo (Department of Psychiatry, Yonsei University College of Medicine, Gangnam Severance Hospital) ;
  • Kim, Ji-Hoon (Department of Psychiatry, Pusan National University School of Medicine) ;
  • Park, Jangho (Department of Psychiatry, University of Ulsan College of Medicine, Ulsan University Hospital) ;
  • Bahn, Geon Ho (Department of Psychiatry, Kyung Hee University School of Medicine) ;
  • Lee, Yeon Jung (Department of Psychiatry, Soonchunhyang University Seoul Hospital) ;
  • Jhung, Kyungun (Department of Psychiatry, International St. Mary's Hospital, Catholic Kwandong University) ;
  • Shin, Dongwon (Department of Psychiatry, Sungkyunkwan University School of Medicine, Kangbuk Samsung Hospital)
  • 투고 : 2017.03.04
  • 심사 : 2017.03.10
  • 발행 : 2017.04.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

The objective of this review is the revision of the Korean practice parameters for the pharmacological treatment of attention-deficit hyperactivity disorder (ADHD) based on the change in the diagnostic system from DSM-IV-TR to DSM-5 and psychopharmacological developments. For the evidence-based approach, the authors conducted a review of the literature, including controlled clinical trials, studies of the side effects of drugs, toxicology and meta-analyses from the United States and Europe, as well as recent research conducted in Korea. The review committee composed of Korean experts on ADHD reviewed the revised parameters. This revised version reveals how to use central nervous system psychostimulants, non-stimulants such as atomoxetine and alpha2 agonists, and other medication for ADHD, and how to manage the adverse effects of such medication. At the end of this revised version, the authors propose recommendations for the pharmacotherapy of ADHD.

키워드

참고문헌

  1. Hunt RD, Arnsten AF, Asbell MD. An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1995;34:50-54. https://doi.org/10.1097/00004583-199501000-00013
  2. Greenhill LL, Pliszka S, Dulcan MK, Bernet W, Arnold V, Beitchman J, et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 2002;41(2 Suppl):26S-49S. https://doi.org/10.1097/00004583-200202001-00003
  3. Subcommittee on Attention-Deficit/Hyperactivity Disorder; Steering Committee on Quality Improvement and Management, Wolraich M, Brown L, Brown RT, DuPaul G, et al. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 2011;128:1007-1022. https://doi.org/10.1542/peds.2011-2654
  4. Kim B, Park E. An observation multi-center study for evaluation of efficacy, safety and parental satisfaction of methylphenidate-OROS in children with ADHD. J Korean Acad Child Adolesc Psychiatry 2005;16:279-285.
  5. Kim Y, Shin MS, Kim JW, Yoo HJ, Cho SC, Kim BN. Neurocognitive effects of switching from methylphenidate-IR to OROSmethylphenidate in children with ADHD. Hum Psychopharmacol 2009;24:95-102. https://doi.org/10.1002/hup.1010
  6. Kim E, Cheon KA, Joung YS, Kim JY, Song DH. The relationship between symptomatic and functional changes of Korean children and adolescents with attention-deficit/hyperactivity disorder treated with osmotic-controlled release oral delivery system-methylphenidate. Clin Neuropharmacol 2015;38:30-35. https://doi.org/10.1097/WNF.0000000000000064
  7. Hwang JW, Kim B, Kim Y, Kim TH, Seo WS, Shin DW, et al. Methylphenidate-osmotic-controlled release oral delivery system treatment reduces parenting stress in parents of children and adolescents with attention-deficit/hyperactivity disorder. Hum Psychopharmacol 2013;28:600-607. https://doi.org/10.1002/hup.2363
  8. Yoo HK, Park S, Wang HR, Lee JS, Kim K, Paik KW, et al. Effect of methylphenidate on the quality of life in children with epilepsy and attention deficit hyperactivity disorder: and open-label study using an osmotic-controlled release oral delivery system. Epileptic Disord 2009;11:301-308.
  9. Hwang JW, Kim BN, Cho SC. Compliance study of methylphenidate IR in the treatment of ADHD. J Korean Acad Chid Adolesc Psychiatry 2004;15:160-167.
  10. Armstrong RB, Damaraju CV, Ascher S, Schwarzman L, O'Neill J, Starr HL. Time course of treatment effect of OROS(R) methylphenidate in children with ADHD. J Atten Disord 2012;16:697-705. https://doi.org/10.1177/1087054711425772
  11. Childress A, Sallee FR. The use of methylphenidate hydrochloride extended-release oral suspension for the treatment of ADHD. Expert Rev Neurother 2013;13:979-988. https://doi.org/10.1586/14737175.2013.833002
  12. Maldonado R. Comparison of the pharmacokinetics and clinical efficacy of new extended-release formulations of methylphenidate. Expert Opin Drug Metab Toxicol 2013;9:1001-1014. https://doi.org/10.1517/17425255.2013.786041
  13. Brams M, Mao AR, Doyle RL. Onset of efficacy of long-acting psychostimulants in pediatric attention-deficit/hyperactivity disorder. Postgrad Med 2008;120:69-88. https://doi.org/10.3810/pgm.2008.09.1909
  14. Michelson D, Allen AJ, Busner J, Casat C, Dunn D, Kratochvil C, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 2002;159:1896-1901. https://doi.org/10.1176/appi.ajp.159.11.1896
  15. Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee FR, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 2001;108:E83. https://doi.org/10.1542/peds.108.5.e83
  16. Michelson D, Adler L, Spencer T, Reimherr FW, West SA, Allen AJ, et al. Atomoxetine i n adults with A DHD: t wo randomized, placebo-controlled studies. Biol Psychiatry 2003;53:112-120. https://doi.org/10.1016/S0006-3223(02)01671-2
  17. Miller MC. W hat is the significance of the new warnings about suicide risk with strattera? Harv Ment Health Lett 2005;22:8.
  18. Kratochvil CJ, Heiligenstein JH, Dittmann R, Spencer TJ, Biederman J, Wernicke J, et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry 2002;41:776-784. https://doi.org/10.1097/00004583-200207000-00008
  19. Newcorn JH, Kratochvil CJ, Allen AJ, Casat CD, Ruff DD, Moore RJ, et al. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry 2008;165:721-730. https://doi.org/10.1176/appi.ajp.2007.05091676
  20. Biederman J, Spencer TJ, Newcorn JH, Gao H, Milton DR, Feldman PD, et al. Effect of comorbid symptoms of oppositional defiant disorder on responses to atomoxetine in children with ADHD: a meta-analysis of controlled clinical trial data. Psychopharmacology (Berl) 2007;190:31-41. https://doi.org/10.1007/s00213-006-0565-2
  21. Kratochvil CJ, Newcorn JH, Arnold LE, Duesenberg D, Emslie GJ, Quintana H, et al. Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. J Am Acad Child Adolesc Psychiatry 2005;44:915-924. https://doi.org/10.1097/01.chi.0000169012.81536.38
  22. Cho S, Lee SI, Yoo H, Song DH, Ahn DH, Shin DW, et al. A randomized, open-label assessment of response to various doses of atomoxetine in korean pediatric outpatients with attention-deficit/hyperactivity disorder. Psychiatry Investig 2011;8:141-148. https://doi.org/10.4306/pi.2011.8.2.141
  23. Briars L, Todd T. A review of pharmacological management of attention-deficit/hyperactivity disorder. J Pediatr Pharmacol Ther 2016;21:192-206.
  24. Posey DJ, McDougle CJ. Guanfacine and guanfacine extended release: treatment for ADHD and related disorders. CNS Drug Rev 2007;13:465-474. https://doi.org/10.1111/j.1527-3458.2007.00026.x
  25. Conners CK, Casat CD, Gualtieri CT, Weller E, Reader M, Reiss A, et al. Bupropion hydrochloride in attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry 1996;35:1314-1321. https://doi.org/10.1097/00004583-199610000-00018
  26. Maneeton N, Maneeton B, Intaprasert S, Woottiluk P. A systematic review of randomized controlled trials of bupropion versus methylphenidate in the treatment of attention-deficit/hyperactivity disorder. Neuropsychiatr Dis Treat 2014;10:1439-1449.
  27. Stuhec M, Munda B, Svab V, Locatelli I. Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis with focus on bupropion. J Affect Disord 2015;178:149-159. https://doi.org/10.1016/j.jad.2015.03.006
  28. Greenhill LL, Biederman J, Boellner SW, Rugino TA, Sangal RB, Earl CQ, et al. A randomized, double-blind, placebo-controlled study of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006;45:503-511. https://doi.org/10.1097/01.chi.0000205709.63571.c9
  29. Kahbazi M, Ghoreishi A, Rahiminejad F, Mohammadi MR, Kamalipour A, Akhondzadeh S. A randomized, double-blind and placebo-controlled trial of modafinil in children and adolescents with attention deficit and hyperactivity disorder. Psychiatry Res 2009;168:234-237. https://doi.org/10.1016/j.psychres.2008.06.024
  30. Biederman J, Swanson JM, Wigal SB, Boellner SW, Earl CQ, Lopez FA; Modafinil ADHD Study Group. A comparison of once-daily and divided doses of modafinil in children with attention-deficit/hyperactivity disorder: a randomized, double-blind, and placebo-controlled study. J Clin Psychiatry 2006;67:727-735. https://doi.org/10.4088/JCP.v67n0506
  31. Canadian ADHD Resource Alliance. Canadian ADHD practice guidelines [cited 2016 Sep 1]. Available from: http://www.caddra.ca/practice-guidelines/download.
  32. Ministry of Health Library. New Zealand guidelines for the assessment and treatment of attention-deficit/hyperactivity disorder [cited 2016 Sep 20]. Available from: http://www.moh.govt.nz/NoteBook/nbbooks.nsf/0/26ADED701C00CA90CC256A9800782552?opendocument.
  33. Perrin JM, Stein MT, Amler RW, Blondis TA, Feldman HM, Meyer BP, et al. Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics 2001; 108:1033-1044. https://doi.org/10.1542/peds.108.4.1033
  34. Yoo HJ, Yang SJ, Shin D, Kang H, Kim BN, Kim JH, et al. The Korean practice parameter for the treatment of attention-deficit hyperactivity disorder (III)-pharmacologic treatment. J Korean Acad Child Adolesc Psychiatry 2007;18:16-25.
  35. American Academy of Child, Adolescent Psychiatry, American Psychiatric Association. ADHD parents medication guide [cited 2016 Sep 1]. Available from: http://www.aacap.org/aacap/press/press_releases/2013/aacap_announces_new_parents_medication_guide_on_adhd.aspx.
  36. Brown TE. ADHD comorbidities: handbook for ADHD complications in children and adults. Washington, DC: American Psychiatric Pub;2009.
  37. Daviss WB, Scott J. A chart review of cyproheptadine for stimulant-induced weight loss. J Child Adolesc Psychopharmacol 2004; 14:65-73. https://doi.org/10.1089/104454604773840508
  38. Perrin JM, Friedman RA, Knilans TK; Black Box Working Group; Section on Cardiology and Cardiac Surgery. Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder. Pediatrics 2008;122:451-453. https://doi.org/10.1542/peds.2008-1573
  39. McCarthy S, Cranswick N, Potts L, Taylor E, Wong IC. Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database. Drug Saf 2009;32:1089-1096. https://doi.org/10.2165/11317630-000000000-00000
  40. Gould MS, Walsh BT, Munfakh JL, Kleinman M, Duan N, Olfson M, et al. Sudden death and use of stimulant medications in youths. Am J Psychiatry 2009;166:992-1001. https://doi.org/10.1176/appi.ajp.2009.09040472
  41. Cooper WO, Habel LA, Sox CM, Chan KA, Arbogast PG, Cheetham TC, et al. ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med 2011;365:1896-1904. https://doi.org/10.1056/NEJMoa1110212
  42. Shin JY, Roughead EE, Park BJ, Pratt NL. Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study. BMJ 2016;353:i2550.
  43. Faraone SV, Biederman J, Morley CP, Spencer TJ. Effect of stimulants on height and weight: a review of the literature. J Am Acad Child Adolesc Psychiatry 2008;47:994-1009.
  44. Kim HW, Kim SO, Shon S, Lee JS, Lee HJ, Choi JH. Effect of methylphenidate on height and weight in Korean children and adolescents with attention-deficit/hyperactivity disorder: a retrospective chart review. J Child Adolesc Psychopharmacol 2014;24: 448-453. https://doi.org/10.1089/cap.2014.0025
  45. Ahn HS. Hong Chang Yee textbook of pediatrics. Seoul: Mirae N Co., Ltd.;2012.
  46. Sullivan MA, Rudnik-Levin F. Attention deficit/hyperactivity disorder and substance abuse. Diagnostic and therapeutic considerations. Ann N Y Acad Sci 2001;931:251-270.
  47. Hammerness P, Joshi G, Doyle R, Georgiopoulos A, Geller D, Spencer T, et al. Do stimulants reduce the risk for cigarette smoking in youth with attention-deficit hyperactivity disorder? A prospective, long-term, open-label study of extended-release methylphenidate. J Pediatr 2013;162:22-27.e2. https://doi.org/10.1016/j.jpeds.2012.06.046
  48. Biederman J, Monuteaux MC, Spencer T, Wilens TE, Macpherson HA, Faraone SV. Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: a naturalistic controlled 10-year follow-up study. Am J Psychiatry 2008;165:597-603. https://doi.org/10.1176/appi.ajp.2007.07091486
  49. Lichtenstein P, Halldner L, Zetterqvist J, Sjolander A, Serlachius E, Fazel S, et al. Medication for attention deficit-hyperactivity disorder and criminality. N Engl J Med 2012;367:2006-2014. https://doi.org/10.1056/NEJMoa1203241
  50. Greenhill LL, Pliszka S, Dulcan MK, Bernet W, Arnold V, Beitchman J, et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 2002;41(2 Suppl):26S-49S. https://doi.org/10.1097/00004583-200202001-00003
  51. Cheng JY, Chen RY, Ko JS, Ng EM. Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis. Psychopharmacology (Berl) 2007;194:197-209. https://doi.org/10.1007/s00213-007-0840-x
  52. Greenhill LL, Newcorn JH, Gao H, Feldman PD. Effect of two different methods of initiating atomoxetine on the adverse event profile of atomoxetine. J Am Acad Child Adolesc Psychiatry 2007;46: 566-572. https://doi.org/10.1097/chi.0b013e3180335ad1
  53. Wietecha LA, Ruff DD, Allen AJ, Greenhill LL, Newcorn JH. Atomoxetine tolerability in pediatric and adult patients receiving different dosing strategies. J Clin Psychiatry 2013;74:1217-1223. https://doi.org/10.4088/JCP.12m07991
  54. Reed VA, Buitelaar JK, Anand E, Day KA, Treuer T, Upadhyaya HP, et al. The safety of atomoxetine for the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a comprehensive review of over a decade of research. CNS Drugs 2016;30:603-628. https://doi.org/10.1007/s40263-016-0349-0
  55. Maneeton N, Maneeton B, Srisurapanont M, Martin SD. Bupropion for adults with attention-deficit hyperactivity disorder: metaanalysis of randomized, placebo-controlled trials. Psychiatry Clin Neurosci 2011;65:611-617. https://doi.org/10.1111/j.1440-1819.2011.02264.x
  56. Kratochvil CJ, Wilens TE, Greenhill LL, Gao H, Baker KD, Feldman PD, et al. Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006;45:919-927. https://doi.org/10.1097/01.chi.0000222788.34229.68
  57. Spencer TJ, Newcorn JH, Kratochvil CJ, Ruff D, Michelson D, Biederman J. Effects of atomoxetine on growth after 2-year treatment among pediatric patients with attention-deficit/hyperactivity disorder. Pediatrics 2005;116:e74-e80. https://doi.org/10.1542/peds.2004-0624
  58. Camporeale A, Day KA, Ruff D, Arsenault J, Williams D, Kelsey DK. Profile of sexual and genitourinary treatment-emergent adverse events associated with atomoxetine treatment: a pooled analysis. Drug Saf 2013;36:663-671. https://doi.org/10.1007/s40264-013-0074-2
  59. Croxtall JD. Clonidine extended-release in attention-deficit hyperactivity disorder: profile report. CNS Drugs 2012;26:277-279. https://doi.org/10.2165/11208310-000000000-00000
  60. Kollins SH, Jain R, Brams M, Segal S, Findling RL, Wigal SB, et al. Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with ADHD. Pediatrics 2011;127:e1406-e1413. https://doi.org/10.1542/peds.2010-1260
  61. Jain R, Segal S, Kollins SH, Khayrallah M. Clonidine extendedrelease tablets for pediatric patients with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2011;50:171-179. https://doi.org/10.1016/j.jaac.2010.11.005
  62. Spencer T, Biederman J, Steingard R, Wilens T. Bupropion exacerbates tics in children with attention-deficit hyperactivity disorder and Tourette's syndrome. J Am Acad Child Adolesc Psychiatry 1993;32:211-214. https://doi.org/10.1097/00004583-199301000-00030
  63. Greenhill L, Kollins S, Abikoff H, McCracken J, Riddle M, Swanson J, et al. Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry 2006;45:1284-1293. https://doi.org/10.1097/01.chi.0000235077.32661.61
  64. Abikoff HB, Vitiello B, Riddle MA, Cunningham C, Greenhill LL, Swanson JM, et al. Methylphenidate effects on functional outcomes in the Preschoolers with attention-deficit/hyperactivity disorder treatment study (PATS). J Child Adolesc Psychopharmacol 2007;17:581-592. https://doi.org/10.1089/cap.2007.0068
  65. Greenhill LL, Swanson JM, Vitiello B, Davies M, Clevenger W, Wu M, et al. Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial. J Am Acad Child Adolesc Psychiatry 2001;40:180-187. https://doi.org/10.1097/00004583-200102000-00012
  66. Wigal SB, Gupta S, Greenhill L, Posner K, Lerner M, Steinhoff K, et al. Pharmacokinetics of methylphenidate in preschoolers with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2007;17:153-164. https://doi.org/10.1089/cap.2007.0043
  67. Ghuman JK, Aman MG, Ghuman HS, Reichenbacher T, Gelenberg A, Wright R, et al. Prospective, naturalistic, pilot study of open-label atomoxetine treatment in preschool children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2009;19:155-166. https://doi.org/10.1089/cap.2008.054
  68. Vitiello B, Lazzaretto D, Yershova K, Abikoff H, Paykina N, Mc-Cracken JT, et al. Pharmacotherapy of the preschool ADHD treatment study (PATS) children growing up. J Am Acad Child Adolesc Psychiatry 2015;54:550-556. https://doi.org/10.1016/j.jaac.2015.04.004
  69. Park S, Cho MJ, Chang SM, Jeon HJ, Cho SJ, Kim BS, et al. Prevalence, correlates, and comorbidities of adult ADHD symptoms in Korea: results of the Korean epidemiologic catchment area study. Psychiatry Res 2011;186:378-383. https://doi.org/10.1016/j.psychres.2010.07.047
  70. Gibbins C, Weiss M. Clinical recommendations in current practice guidelines for diagnosis and treatment of ADHD in adults. Curr Psychiatry Rep 2007;9:420-426. https://doi.org/10.1007/s11920-007-0055-1
  71. Spencer T, Biederman J, Wilens T, Doyle R, Surman C, Prince J, et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2005;57:456-463. https://doi.org/10.1016/j.biopsych.2004.11.043
  72. Biederman J, Mick E, Surman C, Doyle R, Hammerness P, Harpold T, et al. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2006;59:829-835. https://doi.org/10.1016/j.biopsych.2005.09.011
  73. Medori R, Ramos-Quiroga JA, Casas M, Kooij JJ, Niemela A, Trott GE, et al. A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2008;63:981-989. https://doi.org/10.1016/j.biopsych.2007.11.008
  74. Rosler M, Fischer R, Ammer R, Ose C, Retz W. A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder. Eur Arch Psychiatry Clin Neurosci 2009;259:120-129. https://doi.org/10.1007/s00406-008-0845-4
  75. Marchant BK, Reimherr FW, Halls C, Williams ED, Strong RE. OROS methylphenidate in the treatment of adults with ADHD: a 6-month, open-label, follow-up study. Ann Clin Psychiatry 2010;22:196-204.
  76. Wender PH, Reimherr FW, Marchant BK, Sanford ME, Czajkowski LA, Tomb DA. A one year trial of methylphenidate in the treatment of ADHD. J Atten Disord 2011;15:36-45. https://doi.org/10.1177/1087054709356188
  77. Adler LA, Orman C, Starr HL, Silber S, Palumbo J, Cooper K, et al. Long-term safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: an open-label, dose-titration, 1-year study. J Clin Psychopharmacol 2011;31:108-114. https://doi.org/10.1097/JCP.0b013e318203ea0a
  78. Wilens TE, Haight BR, Horrigan JP, Hudziak JJ, Rosenthal NE, Connor DF, et al. Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study. Biol Psychiatry 2005;57:793-801. https://doi.org/10.1016/j.biopsych.2005.01.027
  79. Habel LA, Cooper WO, Sox CM, Chan KA, Fireman BH, Arbogast PG, et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA 2011;306:2673-2683. https://doi.org/10.1001/jama.2011.1830
  80. Adler LA, Liebowitz M, Kronenberger W, Qiao M, Rubin R, Hollandbeck M, et al. Atomoxetine treatment in adults with attentiondeficit/hyperactivity disorder and comorbid social anxiety disorder. Depress Anxiety 2009;26:212-221. https://doi.org/10.1002/da.20549
  81. Adler LA, Spencer T, Brown TE, Holdnack J, Saylor K, Schuh K, et al. Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial. Clin Psychopharmacol 2009;29:44-50. https://doi.org/10.1097/JCP.0b013e318192e4a0
  82. Reimherr FW, Hedges DW, Strong RE, Marchant BK, Williams ED. Bupropion SR in adults with ADHD: a short-term, placebocontrolled trial. Neuropsychiatr Dis Treat 2005;1:245-251.
  83. Kooij JJ, Aeckerlin LP, Buitelaar JK. [Functioning, comorbidity and treatment of 141 adults with attention deficit hyperactivity disorder (ADHD) at a psychiatric outpatient department]. Ned Tijdschr Geneeskd 2001;145:1498-1501.
  84. Turner DC, Clark L, Dowson J, Robbins TW, Sahakian BJ. Modafinil improves cognition and response inhibition in adult attention-deficit/hyperactivity disorder. Biol Psychiatry 2004;55:1031-1040. https://doi.org/10.1016/j.biopsych.2004.02.008
  85. Arnold VK, Feifel D, Earl CQ, Yang R, Adler LA. A 9-week, randomized, double-blind, placebo-controlled, parallel-group, dosefinding study to evaluate the efficacy and safety of modafinil as treatment for adults with ADHD. J Atten Disord 2014;18:133-144. https://doi.org/10.1177/1087054712441969
  86. Wilens TE, Biederman J, Prince J, Spencer TJ, Faraone SV, Warburton R, et al. Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder. Am J Psychiatry 1996;153:1147-1153. https://doi.org/10.1176/ajp.153.9.1147
  87. Spencer T, Biederman J, Harding M, O'Donnell D, Wilens T, Faraone S, et al. Disentangling the overlap between Tourette's disorder and ADHD. J Child Psychol Psychiatry 1998;39:1037-1044. https://doi.org/10.1111/1469-7610.00406
  88. The MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal treatment study of children with ADHD. Arch Gen Psychiatry 1999;56:1073-1086. https://doi.org/10.1001/archpsyc.56.12.1073
  89. Pliszka SR. Patterns of psychiatric comorbidity with attention-deficit/hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 2000;9:525-540, vii. https://doi.org/10.1016/S1056-4993(18)30105-6
  90. The MTA Cooperative Group. Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder: the multimodal treatment study of children with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 1999;56: 1088-1096. https://doi.org/10.1001/archpsyc.56.12.1088
  91. Roessner V, Becker A, Banaschewski T, Rothenberger A. Psychopathological profile in children with chronic tic disorder and co-existing ADHD: additive effects. J Abnorm Child Psychol 2007; 35:79-85. https://doi.org/10.1007/s10802-006-9086-z
  92. Spencer TJ, Biederman J, Faraone S, Mick E, Coffey B, Geller D, et al. Impact of tic disorders on ADHD outcome across the life cycle: findings from a large group of adults with and without ADHD. Am J Psychiatry 2001;158:611-617. https://doi.org/10.1176/appi.ajp.158.4.611
  93. Peterson BS, Pine DS, Cohen P, Brook JS. Prospective, longitudinal study of tic, obsessive-compulsive, and attention-deficit/hyperactivity disorders in an epidemiological sample. J Am Acad Child Adolesc Psychiatry 2001;40:685-695. https://doi.org/10.1097/00004583-200106000-00014
  94. Bloch MH, Panza KE, Landeros-Weisenberger A, Leckman JF. Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders. J Am Acad Child Adolesc Psychiatry 2009;48:884-893. https://doi.org/10.1097/CHI.0b013e3181b26e9f
  95. Pringsheim T, Steeves T. Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders. Cochrane Database Syst Rev 2011;(4):CD007990.
  96. Rizzo R, Gulisano M, Cali PV, Curatolo P. Tourette syndrome and comorbid ADHD: current pharmacological treatment options. Eur J Paediatr Neurol 2013;17:421-428. https://doi.org/10.1016/j.ejpn.2013.01.005
  97. Roessner V, Plessen KJ, Rothenberger A, Ludolph AG, Rizzo R, Skov L, et al. European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment. Eur Child Adolesc Psychiatry 2011;20:173-196.
  98. Geller B, Guttmacher LB, Bleeg M. Coexistence of childhood onset pervasive developmental disorder and attention deficit disorder with hyperactivity. Am J Psychiatry 1981;138:388-389. https://doi.org/10.1176/ajp.138.3.388
  99. Guttmann-Steinmetz S, Gadow KD, DeVincent CJ, Crowell J. Anxiety symptoms in boys with autism spectrum disorder, attention-deficit hyperactivity disorder, or chronic multiple tic disorder and community controls. J Autism Dev Disord 2010;40:1006-1016. https://doi.org/10.1007/s10803-010-0950-x
  100. Corbett BA, Constantine LJ, Hendren R, Rocke D, Ozonoff S. Examining executive functioning in children with autism spectrum disorder, attention deficit hyperactivity disorder and typical development. Psychiatry Res 2009;166:210-222. https://doi.org/10.1016/j.psychres.2008.02.005
  101. Harfterkamp M, van de Loo-Neus G, Minderaa RB, van der Gaag RJ, Escobar R, Schacht A, et al. A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder. J Am Acad Child Adolesc Psychiatry 2012;51:733-741. https://doi.org/10.1016/j.jaac.2012.04.011
  102. Ming X, Gordon E, Kang N, Wagner GC. Use of clonidine in children with autism spectrum disorders. Brain Dev 2008;30:454-460. https://doi.org/10.1016/j.braindev.2007.12.007
  103. Fankhauser MP, Karumanchi VC, German ML, Yates A, Karumanchi SD. A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. J Clin Psychiatry 1992;53:77-82.
  104. Jaselskis CA, Cook EH Jr, Fletcher KE, Leventhal BL. Clonidine treatment of hyperactive and impulsive children with autistic disorder. J Clin Psychopharmacol 1992;12:322-327.
  105. Becker K, Sinzig JK, Holtmann M. 'Attention deficits and subclinical epileptiform discharges: are EEG diagnostics in ADHD optional or essential?' Dev Med Child Neurol 2004;46:501-502.
  106. Austin JK, Harezlak J, Dunn DW, Huster GA, Rose DF, Ambrosius WT. Behavior problems in children before first recognized seizures. Pediatrics 2001;107:115-122. https://doi.org/10.1542/peds.107.1.115
  107. Salpekar JA, Dunn DW. Psychiatric and psychosocial consequences of pediatric epilepsy. Semin Pediatr Neurol 2007;14:181-188. https://doi.org/10.1016/j.spen.2007.08.004
  108. Caplan R. Psychopathology in pediatric epilepsy: role of antiepileptic drugs. Front Neurol 2012;3:163.
  109. Gucuyener K, Erdemoglu AK, Senol S, Serdaroglu A, Soysal S, Kockar AI. Use of methylphenidate for attention-deficit hyperactivity disorder in patients with epilepsy or electroencephalographic abnormalities. J Child Neurol 2003;18:109-112. https://doi.org/10.1177/08830738030180020601
  110. Wernicke JF, Holdridge KC, Jin L, Edison T, Zhang S, Bangs ME, et al. Seizure risk in patients with attention-deficit-hyperactivity disorder treated with atomoxetine. Dev Med Child Neurol 2007;49: 498-502. https://doi.org/10.1111/j.1469-8749.2007.00498.x
  111. Dunn DW, Kronenberger WG. Childhood epilepsy, attention problems, and ADHD: review and practical considerations. Semin Pediatr Neurol 2005;12:222-228. https://doi.org/10.1016/j.spen.2005.12.004
  112. Surman CBH. ADHD in adults. A practical guide to evaluation and management. New York: Humana Press;2013.
  113. Yang SJ, Cheong S, Hong SD. Prevalence and correlates of attention deficit hyperactivity disorder: school-based mental health services in Seoul. J Korean Neuropsychiatr Assoc 2006;45:69-76.
  114. Hong M, Kwack YS, Joung YS, Lee SI, Kim B, Sohn SH, et al. Nationwide rate of attention-deficit hyperactivity disorder diagnosis and pharmacotherapy in Korea in 2008-2011. Asia Pac Psychiatry 2014;6:379-385.
  115. Park TW. Treatment maintenance for ADHD. In: Ahn DH, Kim BS, Du JI, Park TW, Bahn GH, Shin MS, et al., editors. Integrative understanding of ADHD. Seoul: Hakjisa;2015. p.209-220.
  116. Bhang SY, Kwack YS, Joung YS, Lee SI, Kim B, Sohn SH, et al. Factors that affect the adherence to ADHD medications during a treatment continuation period in children and adolescents: a nationwide retrospective cohort study using Korean health insurance date from 2007 to 2011. Psychiatry Investig 2017;14:158-165. https://doi.org/10.4306/pi.2017.14.2.158
  117. Young S, Murphy CM, Coghill D. Avoiding the 'twilight zone': recommendations for the transition of services from adolescence to adulthood for young people with ADHD. BMC Psychiatry 2011;11:174. https://doi.org/10.1186/1471-244X-11-174
  118. Bhang SY, Hwang JW, Kwak YS, Joung YS, Lee S, Kim B, et al. Differences in utilization patterns among medications in children and adolescents with attention-deficit/hyperactivity disorder: a 36-month retrospective study using the Korean Health Insurance Review and Assessment Claims Database. J Korean Med Sci 2016;31:1284-1291. https://doi.org/10.3346/jkms.2016.31.8.1284
  119. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association;1994.
  120. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5(R)). 5th ed. Washington, DC: American Psychiatric Association;2013.
  121. Treuer T, Chan KL, Kim BN, Kunjithapatham G, Wynchank D, Semerci B, et al. Lost in transition: a review of the unmet need of patients with attention deficit/hyperactivity disorder transitioning to adulthood. Asia Pac Psychiatry 2016 Aug 23 [Epub ahead of print]. http://dx.doi.org/10.1111/appy.12254.
  122. Jaber L, Kirsh D, Diamond G, Shuper A. Long-term functional outcomes in Israeli adults diagnosed in childhood with attention deficit hyperactivity disorder. Isr Med Assoc J 2015;17:481-485.
  123. London AS, Landes SD. Attention deficit hyperactivity disorder and adult mortality. Prev Med 2016;90:8-10. https://doi.org/10.1016/j.ypmed.2016.06.021
  124. Dalsgaard S, Ostergaard SD, Leckman JF, Mortensen PB, Pedersen MG. Mortality in children, adolescents, and adults with attention deficit hyperactivity disorder: a nationwide cohort study. Lancet 2015;385:2190-2196. https://doi.org/10.1016/S0140-6736(14)61684-6
  125. Kooij JJ, Michielsen M, Kruithof H, Bijlenga D. ADHD in old age: a review of the literature and proposal for assessment and treatment. Expert Rev Neurother 2016;16:1371-1381. https://doi.org/10.1080/14737175.2016.1204914
  126. Walker JS, Coleman D, Lee J, Squire PN, Friesen BJ. Children's stigmatization of childhood depression and ADHD: magnitude and demographic variation in a national sample. J Am Acad Child Adolesc Psychiatry 2008;47:912-920. https://doi.org/10.1097/CHI.0b013e318179961a
  127. Lee S, Choi JW, Kim KM, Kim JW, Kim S, Kang T, et al. The guideline of diagnosis and treatment of attention-deficit hyperactivity disorder: developed by ADHD translational research center. J Korean Acad Child Adolesc Psychiatry 2016;27:236-266. https://doi.org/10.5765/jkacap.2016.27.4.236
  128. Hong M, Kim B, Hwang JW, Bhang SY, Choi HY, Oh IH, et al. Naturalistic pharmacotherapy compliance among pediatric patients with attention deficit/hyperactivity disorder: a study based on three-year nationwide data. J Korean Med Sci 2016;31:611-616. https://doi.org/10.3346/jkms.2016.31.4.611
  129. Wang LJ, Yang KC, Lee SY, Yang CJ, Huang TS, Lee TL, et al. Initiation and persistence of pharmacotherapy for youths with attention deficit hyperactivity disorder in Taiwan. PLoS One 2016;11:e0161061. https://doi.org/10.1371/journal.pone.0161061
  130. Hwangbo R, Chang H, Hong M, Cho S, Bahn GH. The diagnostic distribution of psychiatric disorders among the population under 19 years old: based on the national insurance data. J Korean Acad Child Adolesc Psychiatry 2016;27:139-145. https://doi.org/10.5765/jkacap.2016.27.2.139
  131. Soendergaard HM, Thomsen PH, Pedersen P, Pedersen E, Poulsen AE, Nielsen JM, et al. Treatment dropout and missed appointments among adults with attention-deficit/hyperactivity disorder: associations with patient- and disorder-related factors. J Clin Psychiatry 2016;77:232-239.

피인용 문헌

  1. Pharmacotherapy for attention-deficit/hyperactivity disorder vol.62, pp.1, 2019, https://doi.org/10.5124/jkma.2019.62.1.49
  2. Clinical Utility and Cut-Off Scores of the Korean Adult Attention-Deficit/Hyperactivity Disorder Rating Scale vol.30, pp.3, 2017, https://doi.org/10.5765/jkacap.190022
  3. A Brief Replication Study Comparing Stimulants and Non-Stimulants for Attention-Deficit/Hyperactivity Disorder Treatment with a Focus on the Compliance, Efficacy, and Satisfaction vol.32, pp.1, 2017, https://doi.org/10.5765/jkacap.200024
  4. Combined Medication with Stimulants and Non-stimulants for Attention-deficit/hyperactivity Disorder vol.19, pp.4, 2021, https://doi.org/10.9758/cpn.2021.19.4.705